SCHEMBL482297

SCHEMBL482297

Clc1ccc(-c2cnc[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.64
ASIC3 Q9UHC3 2/20 0.64
POLB P06746 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
CYP3A4 P08684 3/20 0.63
MAPT P10636 1/20 0.55
LTA4H P09960 1/20 0.55
CYP2D6 P10635 2/20 0.52
CYP2E1 P05181 1/20 0.52
CYP2A6 P11509 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2B6 P20813 1/20 0.52
CYP2C19 P33261 1/20 0.52
CYP11B1 P15538 1/20 0.52
CYP11B2 P19099 1/20 0.52
CYP1A2 P05177 1/20 0.50
GCGR P47871 1/20 0.48
HPGDS O60760 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17800997 0.86 IDO1 (0.75) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL27880327 0.80 IDO1 (0.67) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL872238 0.78 IDO1 (0.64) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL1951516 0.78 IDO1 (1.00) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL17782163 0.78 ASIC3 (1.00) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL14705340 0.78 IDO1 (0.64) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL205481 0.78 IDO1 (0.64) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL496675 0.78 IDO1 (0.64) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL872388 0.78 POLB (1.00) IDO1ASIC3POLBSMN1; SMN2CYP3A4
SCHEMBL27577902 0.78 IDO1 (0.91) IDO1ASIC3POLBSMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101296731-A Novel benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2008-10-29 CN claimed
CN-112034929-B Folding display screen, manufacturing method of folding display screen and terminal equipment 华为技术有限公司 2022-10-18 CN disclosed
EP-3032625-B1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC (JP) 2020-01-08 EP disclosed
EP-3264506-A1 METHOD FOR PRODUCING A FUEL CELL SEPARATOR Nisshinbo Chemical Inc. (JP) 2018-01-03 EP disclosed
EP-2458667-B1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC (JP) 2017-05-24 EP disclosed
EP-2763223-B1 POROUS SEPARATOR FOR FUEL CELLS NISSHINBO CHEMICAL INC (JP) 2016-11-16 EP disclosed
EP-3032625-A1 FUEL CELL SEPARATOR Nisshinbo Chemical Inc. (JP) 2016-06-15 EP disclosed
US-20160156044-A1 FUEL CELL SEPARATOR NISSHINBO CHEMICAL INC. (JP) 2016-06-02 US disclosed
EP-2763223-A1 POROUS SEPARATOR FOR FUEL CELLS Nisshinbo Chemical Inc. (JP) 2014-08-06 EP disclosed
US-8372192-B2 Fuel cell separator NISSHINBO CHEMICAL INC. (JP) 2013-02-12 US disclosed
US-7838553-B2 Benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2010-11-23 US disclosed
US-7812183-B2 Benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2010-10-12 US disclosed
CN-101296731-A Novel benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2008-10-29 CN disclosed
CN-101296925-A Novel benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2008-10-29 CN disclosed
EP-1940516-A2 BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS Janssen Pharmaceutica, N.V. (BE) 2008-07-09 EP disclosed
EP-1937669-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
US-20070072832-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-29 US disclosed
WO-2007027959-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-08 WO disclosed
WO-2007027780-A2 BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-08 WO disclosed
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNN1, KCNN3 IDO1 4077/4885ASIC3 179/4885POLB 4587/4885
US-20070072832-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNN1, KCNN3 IDO1 4077/4885ASIC3 179/4885POLB 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.